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Dissent and resistance
To the Editor: I couldn’t agree more with the sentiments
expressed in your editorial entitled ‘Medicine or politics?’.1
As a profession, knowing all the limitations of antiretroviral
(ARV) therapy, perhaps we should devise for government a
comprehensive management/treatment plan addressing inter
alia the issue of 100% medication compliance in order to avoid
resistance to ARV drugs. Thereafter we should proactively
coerce government into considering treatment authorisation as
is expressed repeatedly in the media.
Oops! To date I have not seen any mention in the press of the
ease of resistance developing with medication default, the
effect of class-specific resistance developing in such situations,
and how best these issues could be addressed. We obviously
have ample experience in the development of drug resistance
to tuberculosis treatment because of poor compliance as a
result of the high number of defaulters. Perhaps reference
should be made to the consequent development of directly
observed treatment (DOT). Yet tuberculosis medication is often
defaulted on because of the side-effects of medication, which
are miniscule in comparison with the side-effects of ARVs
Any comments?
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IUCD insertion at caesarean
section — a new look
To the Editor: The Mirena intra-uterine system was launched
in South Africa in 1999. It has changed the way clinicians view
the intrauterine contraceptive device (IUCD). Apart from the
obvious contraceptive benefits1 the device has many other
advantages over the conventional copper IUCD.2
Immediate postpartum insertion of IUCDs has been
undertaken in China since 1975.3 Expulsion rates are lower
with caesarean insertion compared with postpartum vaginal
insertion.4 Few complications were found in most studies and
in a controlled trial comparing IUCD insertion at caesarean
section with a non-intervention control, no difference was
found in puerperal morbidity or infection.5
Following a presentation on Mirena at the South African
Society of Obstetricians and Gynaecologists (SASOG) Sun City
2001 congress, the possibility of Mirena insertion at caesarean
section was discussed with Dr David Horwell (UK expert) and
certain possible clinical advantages may be postulated: (i) the
progesterone release mimics the normal involuting puerperal
environment of the uterus, which may decrease lochia and
dysfunctional bleeding; (ii) after cessation of breast-feeding, the
uterus will continue to behave as though the woman is breast-
feeding, with persisting amenorrhoea or oligomenorrhoea for
the 5 years of Mirena’s licensed duration of use; (iii) the inert
nature of the device makes intrauterine inflammatory response
very unlikely and may therefore decrease the possibility of
sepsis compared with a copper device; (iv) provision of long-
term but reversible contraception, with effectiveness similar to
that of female sterilisation;6 and (v) the wider diameter and
inert nature of the device may make expulsion less likely than
with a conventional copper IUCD.
After the SASOG congress and after reviewing the literature,
the author has commenced insertion of the Mirena IUCD at
caesarean section. So far 4 patients have undergone placement
of the device at the time of surgery, after full counselling. The
device was inserted just before closure of the lower segment. A
fundal insertion is obtained and the device is not sutured.
Strings are cut at the level of the lower segment. Prophylactic
antibiotics are given as a routine at surgery. To date all 4
patients have had no dysfunctional bleeding and are extremely
satisfied. Although the device has not been removed after
caesarean section no difficulty is usually found with removal
with the threads cut short high in the cervical canal.
The author is happy to collate and arrange with interested
practitioners an audit of ‘The South African experience of
Mirena insertion at caesarean section’. No such experience has
been shared to date and I am sure our international colleagues
would be keen to see the results from South Africa!
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